drugset / Trial / NCT01446094

Diagnostic Study of Rapid Regadenoson Stress Cardiovascular Magnetic Resonance (CMR) to Detect Coronary Artery Disease

NCT01446094

NaSingle-groupOpen-labelDiagnostic

Summary

This study is designed to evaluate the feasibility and diagnostic performance of a novel rapid regadenoson stress CMR protocol for detecting of obstructive coronary artery disease.

Timeline

Start
2011-08
Primary completion
2018-06
Completion
2018-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Regadenoson Diagnostic / imaging agent 0.4 mg Intravenous